Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Recurrent urinary tract infections (RUTIS) continue to be a major health problem in women and
are now complicated by increasing antibiotic resistance. New preventive approaches are
needed. Because most women with RUTI lack the normal protective Lactobacillus (LB) in their
vaginal flora, we hypothesized that restoration of LB would reduce RUTIS. In this trail,
women with recent UTI are randomized to receive either LB or placebo vaginal capsules and are
followed for side effects, for colonization with LB and for occurrence of RUTI over hte next
four months.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Osel, Inc.